Latest Content

Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

The OTC lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

The evolution of IPL is not limited to its expanding role in ocular surface disease.

Catch up on the top stories in optometry during the week of August 24-28.

The findings extend prior Asian efficacy data to a diverse North American cohort for Stellest lenses.

Optometrists share advice on the best practices for ensuring students are prepared for the new school year and how clinicians can leverage the influx to grow their practice.

The agency assigned a PDUFA target action date of April 30, 2027.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

The company announced phase 2 results of a dual-action lifitegrast/perfluorohexyloctane dry eye drop alongside positive phase 1b results for BL1332, a first-in-class TRPV1 antagonist for ocular surface pain.

Teacher-led vision screening identified about 3 in 4 children with refractive error and correctly cleared most unaffected students.

The FDA has expanded the indication to include improvement of meibomian gland function in adult patients with evaporative dry eye disease due to MGD, making it the first treatment with this indication.

This review summarizes major contact lens risks, solution-related adverse effects, higher-risk populations, and practical prevention strategies for optometric practice.